1 |
McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40
DOI
ScienceOn
|
2 |
Meredith R, Shen S, Macey D, et al. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm 2003;18:393-404
DOI
ScienceOn
|
3 |
Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9
|
4 |
Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46
|
5 |
Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435-50
DOI
ScienceOn
|
6 |
Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalentbispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003;9:3886S-96S
|
7 |
Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002 15;20:2453-63
DOI
ScienceOn
|
8 |
Goldenberg, DM. Therapeutic use of radiolabeled antibodies: hematopoietic tumors. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed. London, UK: Churchill Livingstone; 2004:428-34
|
9 |
Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimization of anti- carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 2003;9:3973S-81S
|
10 |
Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003;44:400-11
|
11 |
Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447-54
|
12 |
Paganelli G, Chinol M. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6
DOI
ScienceOn
|
13 |
Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000;6:3095-102
|
14 |
Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidinbiotin system. Int J Biol Markers 1993;8:155-9
DOI
|
15 |
Wong JY, Shibata S, Williams LE, et al. A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52
|
16 |
Liu G, He J, Dou S, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004;31:417-24
DOI
|
17 |
Meredith RF, Khazaeli MB, Macey DJ, et al. Phase II study of interferonenhanced I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999;5:3254S-8S
|
18 |
Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001;39:181-94
DOI
ScienceOn
|
19 |
Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003;102:2351-7
DOI
ScienceOn
|
20 |
Goldenberg DM, Chang CH, Sharkey RM, et al. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:777-80
DOI
ScienceOn
|
21 |
Liu CB, Liu GZ, Liu N, et al. Radiolabeling morpholinos with Y, In, Re and Tc. Nucl Med Biol 2003;30:207-14
DOI
ScienceOn
|
22 |
Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, De Labriolle-Vaylet C, Barbet J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med 2001;45:201-6
|
23 |
Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-66
|
24 |
Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl):115S-27S
|
25 |
Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20B-cell lymphoma: long term follow-up of a phase I/II study. Blood 2004;103:4429-31
DOI
ScienceOn
|
26 |
Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm 2000;15:347-55
DOI
ScienceOn
|
27 |
Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004;103:1485-94
DOI
ScienceOn
|
28 |
Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen- producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999;5(suppl): 3183S-9S
|
29 |
Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with 111indium, 67gallium, or 90yttrium. Clin Cancer Res 2001;7:1505-10
|
30 |
Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713
|
31 |
Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med 2003;44:1541-3
|
32 |
Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985;316:265-8
DOI
ScienceOn
|
33 |
Paganelli G, Pervez S, Siccardi AG, et al. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer 1990;45:1184-9
DOI
|
34 |
Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine- 131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997;15:1518-28
DOI
|
35 |
Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991;51:6650-5
|
36 |
Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-1302
|
37 |
Pressman D, Korngold L. The in vivo localization of anti-wagner osteogenicsarcoma antibodies. Cancer 1953;6:619-23
DOI
ScienceOn
|
38 |
Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503
DOI
ScienceOn
|
39 |
Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513-24
DOI
ScienceOn
|
40 |
Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300
DOI
|
41 |
Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553-63
|
42 |
Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9:3991S-4S
|
43 |
Bethge WA, Sandmaier BM. Targeted Cancer Therapy and Immunosuppression Using Radiolabeled Monoclonal Antibodies. Semin Oncol 2004;31:68-82
DOI
ScienceOn
|
44 |
Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66
|
45 |
Liu G, Liu C, Zhang S, et al. Investigations of 99mTc morpholino pretargeting in mice. Nucl Med Commun 2003;24:697-705
DOI
ScienceOn
|
46 |
Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6
|
47 |
Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999;14:153-66
DOI
ScienceOn
|
48 |
Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with Y ibritumomab tiuxetan (zevalin). Semin Oncol 2003; 30(suppl):6-10
|
49 |
Meredith RF, Khazaeli MB, Plott WE, et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 1996;2:1811-8
|
50 |
McQuarrie SA, Xiao Z, Miller GG, Mercer JR, Suresh MR. Modern trends in radioimmunotherapy of cancer: pretargeting strategies for the treatment of ovarian cancer. Q J Nucl Med 2001;45:160-6
|
51 |
Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70
DOI
ScienceOn
|